Indian court rejects AstraZeneca’s injunction request

The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Big Pharma

India regulator U-turns on controversial generics-only policy

31 August 2023 National Medical Commission has put new regulations on hold that would have made prescribing generics mandatory | Move comes after pressure from doctors’ organisation and pharma firms.

More on this story

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Big Pharma

India regulator U-turns on controversial generics-only policy

More on this story

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Generics

AstraZeneca loses major generics appeal in India

22 July 2021 The Delhi High Court has cleared the way for a slew of generic diabetes drugs to arrive on the Indian market after it rejected AstraZeneca’s request for a blocking order.

Big Pharma

India regulator U-turns on controversial generics-only policy